Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00279201




Registration number
NCT00279201
Ethics application status
Date submitted
15/12/2005
Date registered
19/01/2006
Date last updated
21/02/2011

Titles & IDs
Public title
The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)
Scientific title
The Durability of Twice-Daily Insulin Lispro Low Mixture Compared to Once-Daily Insulin Glargine When Added to Existing Oral Therapy in Patients With Type 2 Diabetes and Inadequate Glycemic Control
Secondary ID [1] 0 0
F3Z-US-IOOV
Secondary ID [2] 0 0
10455
Universal Trial Number (UTN)
Trial acronym
IOOV
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Diabetes Mellitus, Type 2 0 0
Condition category
Condition code
Metabolic and Endocrine 0 0 0 0
Diabetes

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Insulin glargine
Treatment: Drugs - Lispro Low Mix
Treatment: Drugs - Lispro Mid Mix
Treatment: Drugs - Lispro

Active comparator: Insulin glargine - Initiation Phase: Insulin glargine for 24 weeks Maintenance: Up to an additional 2 years of insulin glargine if glycosylated hemoglobin (HbA1c) less than or equal to 7.0 at 24 weeks.

Experimental: Lispro Low Mix - Initiation Phase: Lispro Low Mix (LM) for 24 weeks Maintenance Phase: Up to an additional 2 years of Lispro LM if HbA1c less than or equal to 7.0 at 24 weeks.

Experimental: Lispro Mid Mix prior Lispro Low Mix addendum - Following Lispro LM Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, participants could be randomized to receive Lispro Mid Mix for 24 weeks in the Intensification Addendum Phase.

Experimental: Lispro Low Mix prior Glargine addendum - Following Insulin Glargine Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, participants could be randomized to receive Lispro Low Mix for 24 weeks in the Intensification Addendum Phase

Active comparator: Basal bolus prior Lispro Low Mix addendum - Following Lispro LM Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, participants could be randomized to receive Basal Bolus therapy (combination of insulin glargine and lispro) for 24 weeks in the Intensification Addendum Phase.

Active comparator: Basal bolus prior Glargine addendum - Following Insulin Glargine Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, participants could be randomized to receive Basal Bolus therapy (combination of insulin glargine and lispro) for 24 weeks in the Intensification Addendum Phase.


Treatment: Drugs: Insulin glargine
Subcutaneous injection daily

Treatment: Drugs: Lispro Low Mix
Subcutaneous injection twice daily.

Treatment: Drugs: Lispro Mid Mix
Lispro Mid Mix subcutaneous injection 3 times daily.

Treatment: Drugs: Lispro
Lispro subcutaneous injection 3 times daily.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
INITIATION: 24-Week Endpoint Glycosylated Hemoglobin (HbA1c)
Timepoint [1] 0 0
Endpoint (Initiation: Week 24)
Primary outcome [2] 0 0
MAINTENANCE: Duration of Time HbA1c Maintained at Goal by Initiation Regimen (Insulin Glargine or Lispro Low Mix)
Timepoint [2] 0 0
Endpoint (Last Observation Carried Forward [LOCF]) (Maintenance: up to 2.5 years)
Primary outcome [3] 0 0
ADDENDUM: 24-Week Endpoint HbA1c
Timepoint [3] 0 0
Endpoint (Addendum) (24 weeks: Week 48)
Secondary outcome [1] 0 0
INITIATION: Change in HbA1c From Baseline to 24 Weeks
Timepoint [1] 0 0
Baseline (Initiation) to Endpoint (LOCF, Week 24)
Secondary outcome [2] 0 0
INITIATION: Percentage of Participants With HbA1c < or = 7.0%, HbA1c <7.0%, and HbA1c < or = 6.5% at Endpoint
Timepoint [2] 0 0
Endpoint (Initiation: Week 24)
Secondary outcome [3] 0 0
INITIATION: HbA1c
Timepoint [3] 0 0
Baseline (Initiation), Week 12, Week 24, Endpoint (LOCF)
Secondary outcome [4] 0 0
INITIATION: 7-point Self-monitored Plasma Glucose (SMPG) Profiles and Postprandial Excursions
Timepoint [4] 0 0
Endpoint (LOCF) (Initiation: Week 24)
Secondary outcome [5] 0 0
INITIATION: Change From Baseline to Endpoint in 1,5 Anhydroglucitol (1,5 AG)
Timepoint [5] 0 0
Baseline (Initiation), Endpoint (Week 24)
Secondary outcome [6] 0 0
INITIATION: Incremental Change From Baseline in Body Weight
Timepoint [6] 0 0
Baseline (Initiation), Weeks 6, 12, 18, 24, Endpoint (LOCF)
Secondary outcome [7] 0 0
INITIATION: Body Weight
Timepoint [7] 0 0
Baseline (Initiation), Weeks 6, 12, 18, 24, Endpoint (LOCF)
Secondary outcome [8] 0 0
INITIATION: Percentage of Participants With Self-reported Hypoglycemic Episodes
Timepoint [8] 0 0
Baseline (Initiation), Endpoint (Week 24), Overall (sum of frequencies of hypoglycemic episodes after baseline ([Week 0]).
Secondary outcome [9] 0 0
INITIATION: Rate of Self-reported Hypoglycemic Episodes
Timepoint [9] 0 0
Endpoint (Initiation: Week 24), Overall (incidence of hypoglycemic episodes after baseline [Week 0])
Secondary outcome [10] 0 0
INITIATION: Insulin Dose
Timepoint [10] 0 0
Weeks 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, Endpoint (LOCF)
Secondary outcome [11] 0 0
INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal at Week 24 - Age
Timepoint [11] 0 0
Endpoint (Initiation: Week 24)
Secondary outcome [12] 0 0
INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal at Week 24 - Origin
Timepoint [12] 0 0
Endpoint (Initiation: Week 24)
Secondary outcome [13] 0 0
INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal at Week 24 - Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)
Timepoint [13] 0 0
Endpoint (Initiation: Week 24)
Secondary outcome [14] 0 0
INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal at Week 24 - HbA1c
Timepoint [14] 0 0
Endpoint (Initiation: Week 24)
Secondary outcome [15] 0 0
INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal at Week 24 - Baseline HbA1c Percentage Group
Timepoint [15] 0 0
Endpoint (Initiation: Week 24)
Secondary outcome [16] 0 0
INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal at Week 24 - 1,5 AG
Timepoint [16] 0 0
Endpoint (Initiation: Week 24)
Secondary outcome [17] 0 0
INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal at Week 24 - Pre Meals Blood Glucose, Post Meals Blood Glucose, Average of All Blood Glucose, and Fasting Blood Glucose
Timepoint [17] 0 0
Endpoint (Initiation: Week 24)
Secondary outcome [18] 0 0
INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal - Oral Diabetes Medication at Baseline
Timepoint [18] 0 0
Endpoint (Initiation: Week 24)
Secondary outcome [19] 0 0
MAINTENANCE: HbA1c at Specified Visits and Endpoint
Timepoint [19] 0 0
Baseline (Week 0), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, Endpoint (LOCF) (up to 2.5 years)
Secondary outcome [20] 0 0
MAINTENANCE: 7-point SMPG Profiles and Postprandial Excursions
Timepoint [20] 0 0
Baseline (Maintenance: Week 24), Endpoint (LOCF) (up to 2.5 years)
Secondary outcome [21] 0 0
MAINTENANCE: Rate of Increase in HbA1c
Timepoint [21] 0 0
Endpoint (LOCF) (Maintenance: up to 2.5 years)
Secondary outcome [22] 0 0
MAINTENANCE: Percentage of Participants With HbA1c < or = 7.0%, HbA1c <7.0, and HbA1c < or = 6.5%
Timepoint [22] 0 0
Endpoint (LOCF) (Maintenance: up to 2.5 years)
Secondary outcome [23] 0 0
MAINTENANCE: Incremental Change From Baseline in Body Weight
Timepoint [23] 0 0
Baseline (Week 0), Weeks 24, 36, 48, 60, 72, 84, 96, 108, 120, Endpoint (LOCF) (Maintenance) (up to 2.5 years)
Secondary outcome [24] 0 0
MAINTENANCE: Body Weight
Timepoint [24] 0 0
Baseline (Week 0), Weeks 24, 36, 48, 60, 72, 84, 96, 108, 120, Endpoint (LOCF) (Maintenance) (up to 2.5 years)
Secondary outcome [25] 0 0
MAINTENANCE: Insulin Dose
Timepoint [25] 0 0
Weeks 24, 36, 48, 60, 72, 84, 96, 108, 120, Endpoint (LOCF) (Maintenance) (up to 2.5 years)
Secondary outcome [26] 0 0
MAINTENANCE: Percentage of Participants With Self-reported Hypoglycemic Episodes
Timepoint [26] 0 0
Endpoint (LOCF) (Maintenance) (up to 2.5 years), Overall (incidence of hypoglycemic episodes after baseline (Week 0)
Secondary outcome [27] 0 0
MAINTENANCE: Rate of Self-reported Hypoglycemic Episodes
Timepoint [27] 0 0
Endpoint (LOCF) (Maintenance) (up to 2.5 years), Overall (incidence of hypoglycemic episodes after baseline [Week 0])
Secondary outcome [28] 0 0
MAINTENANCE: Change From Baseline in 1,5-Anhydroglucitol
Timepoint [28] 0 0
Baseline (Maintenance: Week 24), Endpoint (LOCF) (up to 2.5 years)
Secondary outcome [29] 0 0
MAINTENANCE: Change From Baseline to Endpoint in HbA1c
Timepoint [29] 0 0
Baseline (Week 0), Week 24, Endpoint (LOCF) (Maintenance) (up to 2.5 years)
Secondary outcome [30] 0 0
MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - Duration of Diabetes
Timepoint [30] 0 0
Endpoint (LOCF) (Maintenance) (up to 2.5 years)
Secondary outcome [31] 0 0
MAINTENANCE: Participant Demographics of Lispro LM Participants Who Did Versus Did Not Maintain HbA1c Goal - Duration of Diabetes
Timepoint [31] 0 0
Endpoint (LOCF) (Maintenance) (up to 2.5 years)
Secondary outcome [32] 0 0
MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - Duration of Diabetes Group
Timepoint [32] 0 0
Endpoint (LOCF) (Maintenance) (up to 2.5 years)
Secondary outcome [33] 0 0
MAINTENANCE: Participant Demographics of Lispro LM Participants Who Did Versus Did Not Maintain HbA1c Goal - Duration of Diabetes Group
Timepoint [33] 0 0
Endpoint (LOCF) (Maintenance) (up to 2.5 years)
Secondary outcome [34] 0 0
MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - Baseline HbA1c
Timepoint [34] 0 0
Endpoint (LOCF) (Maintenance) (up to 2.5 years)
Secondary outcome [35] 0 0
MAINTENANCE: Participant Demographics of Lispro LM Participants Who Did Versus Did Not Maintain HbA1c Goal - Baseline HbA1c
Timepoint [35] 0 0
Endpoint (LOCF) (Maintenance) (up to 2.5 years)
Secondary outcome [36] 0 0
MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - Baseline HbA1c Group
Timepoint [36] 0 0
Endpoint (LOCF) (Maintenance) (up to 2.5 years)
Secondary outcome [37] 0 0
MAINTENANCE: Participant Demographics of Lispro LM Participants Who Did Versus Did Not Maintain HbA1c Goal - Baseline HbA1c Group
Timepoint [37] 0 0
Endpoint (LOCF) (Maintenance) (up to 2.5 years)
Secondary outcome [38] 0 0
MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - Oral Diabetes Medicine at Baseline
Timepoint [38] 0 0
Endpoint (LOCF) (Maintenance) (up to 2.5 years)
Secondary outcome [39] 0 0
MAINTENANCE: Participant Demographics of Lispro LM Participants Who Did Versus Did Not Maintain HbA1c Goal - Oral Diabetes Medicine at Baseline
Timepoint [39] 0 0
Endpoint (LOCF) (Maintenance) (up to 2.5 years)
Secondary outcome [40] 0 0
MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - 1,5 AG
Timepoint [40] 0 0
Endpoint (LOCF) (Maintenance) (up to 2.5 years)
Secondary outcome [41] 0 0
MAINTENANCE: Participant Demographics of Lispro LM Participants Who Did Versus Did Not Maintain HbA1c Goal - 1,5 AG
Timepoint [41] 0 0
Endpoint (LOCF) (Maintenance) (up to 2.5 years)
Secondary outcome [42] 0 0
MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - Mean of Post Meals Blood Glucose and Average of All Blood Glucose
Timepoint [42] 0 0
Endpoint (LOCF) (Maintenance) (up to 2.5 years)
Secondary outcome [43] 0 0
MAINTENANCE: Participant Demographics of Lispro LM Participants Who Did Versus Did Not Maintain HbA1c Goal - Mean of Post Meals Blood Glucose and Average of All Blood Glucose
Timepoint [43] 0 0
Endpoint (LOCF) (Maintenance) (up to 2.5 years)
Secondary outcome [44] 0 0
ADDENDUM: Change in HbA1c From Point of Second Randomization (Addendum Baseline) to Endpoint
Timepoint [44] 0 0
Baseline (Addendum: Week 24), Endpoint (24 weeks [Week 48])
Secondary outcome [45] 0 0
ADDENDUM: Percentage of Participants With HbA1c < or = 7.0%, HbA1c < 7.0%, and < or = 6.5%
Timepoint [45] 0 0
Endpoint (Addendum: 24 weeks [Week 48])
Secondary outcome [46] 0 0
ADDENDUM: 7-point SMPG Profiles
Timepoint [46] 0 0
Endpoint (Addendum: 24 weeks [Week 48])
Secondary outcome [47] 0 0
ADDENDUM: Incremental Change From Baseline in Body Weight
Timepoint [47] 0 0
Baseline (Addendum: Week 24), Weeks 6 (30 Weeks), 12 (36 Weeks), 24 (48 Weeks), Endpoint (LOCF)
Secondary outcome [48] 0 0
ADDENDUM: Body Weight
Timepoint [48] 0 0
Baseline (Addendum Week 24), Weeks 6 (30 weeks), 12 (36 weeks), 24 (48 weeks), Endpoint (LOCF)
Secondary outcome [49] 0 0
ADDENDUM: Insulin Dose
Timepoint [49] 0 0
Baseline (Addendum: Week 24), Weeks 1 (25 weeks), 2 (26 weeks), 3 (27 weeks), 4 (28 weeks), 5 (25 weeks), 6 (26 weeks), 8 (32 weeks), 10 (34 weeks), 12 (36 weeks), 24 (48 weeks), Endpoint (LOCF)
Secondary outcome [50] 0 0
ADDENDUM: Percentage of Participants With Self-reported Hypoglycemic Episodes
Timepoint [50] 0 0
Weeks 6 (Addendum: 30 weeks), 12 (36 weeks), 24 (48 weeks), Endpoint (LOCF)
Secondary outcome [51] 0 0
ADDENDUM: Rate of Self-reported Hypoglycemic Episodes
Timepoint [51] 0 0
Endpoint (Addendum 24 weeks), Overall (mean yearly rate of hypoglycemia during addendum phase
Secondary outcome [52] 0 0
ADDENDUM: Change From Baseline in 1,5-Anhydroglucitol to Week 24
Timepoint [52] 0 0
Baseline (addendum: 24 weeks), Endpoint (24 weeks: Week 48)
Secondary outcome [53] 0 0
ADDENDUM: HbA1c at Specified Visits and Endpoint
Timepoint [53] 0 0
Baseline (Addendum: 24 weeks), Weeks 12, 24, Endpoint (24 weeks: Week 48)

Eligibility
Key inclusion criteria
* Must have type 2 diabetes.
* Must be at least 30 and less than 80 years of age at the time of Visit 1.
* Must be on at least two oral antidiabetes medications for at least 90 days.
* Must have an HbA1c 1.2 to 2.0 times the upper limit of normal reference range at the local lab.
Minimum age
30 Years
Maximum age
79 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Must not have used insulin on a regular basis in the last 12 months.
* Must not have had more than one episode of severe hypoglycemia in the last 24 weeks.
* Must not have a body mass index (BMI) of greater than 45 (morbid obesity).
* Must not have clinically significant hematologic, oncologic, renal, cardiac, hepatic, or gastrointestinal disease.
* Must not be pregnant or intend to get pregnant during course of the study.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 4
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/12/2005
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/11/2009
Sample size
Target
Accrual to date
Final
2091
Recruitment in Australia
Recruitment state(s)
NSW,SA,TAS,VIC,WA
Recruitment hospital [1] 0 0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Kingswood Penrith
Recruitment hospital [2] 0 0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Elizabeth Vale
Recruitment hospital [3] 0 0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Keswick
Recruitment hospital [4] 0 0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Burnie
Recruitment hospital [5] 0 0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Box Hill
Recruitment hospital [6] 0 0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Nedlands
Recruitment postcode(s) [1] 0 0
2747 - Kingswood Penrith
Recruitment postcode(s) [2] 0 0
5112 - Elizabeth Vale
Recruitment postcode(s) [3] 0 0
5035 - Keswick
Recruitment postcode(s) [4] 0 0
7320 - Burnie
Recruitment postcode(s) [5] 0 0
3128 - Box Hill
Recruitment postcode(s) [6] 0 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Colorado
Country [6] 0 0
United States of America
State/province [6] 0 0
Connecticut
Country [7] 0 0
United States of America
State/province [7] 0 0
Florida
Country [8] 0 0
United States of America
State/province [8] 0 0
Georgia
Country [9] 0 0
United States of America
State/province [9] 0 0
Hawaii
Country [10] 0 0
United States of America
State/province [10] 0 0
Idaho
Country [11] 0 0
United States of America
State/province [11] 0 0
Illinois
Country [12] 0 0
United States of America
State/province [12] 0 0
Indiana
Country [13] 0 0
United States of America
State/province [13] 0 0
Iowa
Country [14] 0 0
United States of America
State/province [14] 0 0
Kansas
Country [15] 0 0
United States of America
State/province [15] 0 0
Kentucky
Country [16] 0 0
United States of America
State/province [16] 0 0
Louisiana
Country [17] 0 0
United States of America
State/province [17] 0 0
Maine
Country [18] 0 0
United States of America
State/province [18] 0 0
Maryland
Country [19] 0 0
United States of America
State/province [19] 0 0
Massachusetts
Country [20] 0 0
United States of America
State/province [20] 0 0
Michigan
Country [21] 0 0
United States of America
State/province [21] 0 0
Minnesota
Country [22] 0 0
United States of America
State/province [22] 0 0
Missouri
Country [23] 0 0
United States of America
State/province [23] 0 0
Nevada
Country [24] 0 0
United States of America
State/province [24] 0 0
New Hampshire
Country [25] 0 0
United States of America
State/province [25] 0 0
New Jersey
Country [26] 0 0
United States of America
State/province [26] 0 0
New York
Country [27] 0 0
United States of America
State/province [27] 0 0
North Carolina
Country [28] 0 0
United States of America
State/province [28] 0 0
North Dakota
Country [29] 0 0
United States of America
State/province [29] 0 0
Ohio
Country [30] 0 0
United States of America
State/province [30] 0 0
Oklahoma
Country [31] 0 0
United States of America
State/province [31] 0 0
Oregon
Country [32] 0 0
United States of America
State/province [32] 0 0
Pennsylvania
Country [33] 0 0
United States of America
State/province [33] 0 0
South Carolina
Country [34] 0 0
United States of America
State/province [34] 0 0
Tennessee
Country [35] 0 0
United States of America
State/province [35] 0 0
Texas
Country [36] 0 0
United States of America
State/province [36] 0 0
Utah
Country [37] 0 0
United States of America
State/province [37] 0 0
Vermont
Country [38] 0 0
United States of America
State/province [38] 0 0
Washington
Country [39] 0 0
United States of America
State/province [39] 0 0
Wisconsin
Country [40] 0 0
Argentina
State/province [40] 0 0
Buenos Aires
Country [41] 0 0
Argentina
State/province [41] 0 0
Mar Del Plata
Country [42] 0 0
Argentina
State/province [42] 0 0
Pilar
Country [43] 0 0
Brazil
State/province [43] 0 0
Curitiba
Country [44] 0 0
Brazil
State/province [44] 0 0
Porto Alegre
Country [45] 0 0
Brazil
State/province [45] 0 0
Setor Oeste/Goiania
Country [46] 0 0
Brazil
State/province [46] 0 0
São Paulo
Country [47] 0 0
Canada
State/province [47] 0 0
Alberta
Country [48] 0 0
Canada
State/province [48] 0 0
Manitoba
Country [49] 0 0
Canada
State/province [49] 0 0
New Brunswick
Country [50] 0 0
Canada
State/province [50] 0 0
Ontario
Country [51] 0 0
Canada
State/province [51] 0 0
Quebec
Country [52] 0 0
Greece
State/province [52] 0 0
Athens
Country [53] 0 0
Greece
State/province [53] 0 0
Nikaias - Piraeus
Country [54] 0 0
Greece
State/province [54] 0 0
Thessaloniki
Country [55] 0 0
Hungary
State/province [55] 0 0
Eger
Country [56] 0 0
Hungary
State/province [56] 0 0
Pecs
Country [57] 0 0
Hungary
State/province [57] 0 0
Szekszard
Country [58] 0 0
Hungary
State/province [58] 0 0
Szentes
Country [59] 0 0
India
State/province [59] 0 0
Ahemdabad
Country [60] 0 0
India
State/province [60] 0 0
Aligarh
Country [61] 0 0
India
State/province [61] 0 0
Bangalore
Country [62] 0 0
India
State/province [62] 0 0
Coimbatore
Country [63] 0 0
India
State/province [63] 0 0
Hyderabaad
Country [64] 0 0
India
State/province [64] 0 0
Karnal/Haryana
Country [65] 0 0
India
State/province [65] 0 0
Trivandrum
Country [66] 0 0
Netherlands
State/province [66] 0 0
Amsterdam
Country [67] 0 0
Netherlands
State/province [67] 0 0
Brunssum
Country [68] 0 0
Netherlands
State/province [68] 0 0
Emmen
Country [69] 0 0
Netherlands
State/province [69] 0 0
Hoogeveen
Country [70] 0 0
Netherlands
State/province [70] 0 0
Nijmegen
Country [71] 0 0
Netherlands
State/province [71] 0 0
Venlo
Country [72] 0 0
Netherlands
State/province [72] 0 0
Zwijndrecht
Country [73] 0 0
Puerto Rico
State/province [73] 0 0
Bayamon
Country [74] 0 0
Puerto Rico
State/province [74] 0 0
Carolina
Country [75] 0 0
Puerto Rico
State/province [75] 0 0
Orcorvis
Country [76] 0 0
Puerto Rico
State/province [76] 0 0
Ponce
Country [77] 0 0
Puerto Rico
State/province [77] 0 0
Rio Piedras
Country [78] 0 0
Puerto Rico
State/province [78] 0 0
San Juan
Country [79] 0 0
Romania
State/province [79] 0 0
Brasov
Country [80] 0 0
Romania
State/province [80] 0 0
Bucharest
Country [81] 0 0
Romania
State/province [81] 0 0
Cluj-Napoca
Country [82] 0 0
Romania
State/province [82] 0 0
Targu-Mures
Country [83] 0 0
Romania
State/province [83] 0 0
Timisoara
Country [84] 0 0
Spain
State/province [84] 0 0
Alcira
Country [85] 0 0
Spain
State/province [85] 0 0
Dos Hermanas
Country [86] 0 0
Spain
State/province [86] 0 0
Madrid
Country [87] 0 0
Spain
State/province [87] 0 0
Malaga
Country [88] 0 0
Spain
State/province [88] 0 0
Mosteles
Country [89] 0 0
Spain
State/province [89] 0 0
Requena
Country [90] 0 0
Spain
State/province [90] 0 0
Santander

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Eli Lilly and Company
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study will compare insulin lispro low mixture \[LM\] and insulin glargine both in combination with the patient's oral diabetes medicines, for their ability to control blood sugar in patients with type 2 diabetes and compare insulin lispro LM to insulin glargine with regard to the length of time that the overall blood sugar can be controlled.

This study will also determine whether the safety of insulin lispro LM and any side effects that might be associated with it are different from those observed with insulin glargine, both in combination with the patient's oral diabetes medications.

The addendum study (Intensification Addendum) will compare how different insulin treatments work to control blood sugar in patients whose diabetes could not be controlled by either insulin lispro LM or insulin glargine.
Trial website
https://clinicaltrials.gov/study/NCT00279201
Trial related presentations / publications
Herman WH, Dungan KM, Wolffenbuttel BH, Buse JB, Fahrbach JL, Jiang H, Martin S. Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1,5-anhydroglucitol in over 2000 patients with type 2 diabetes. J Clin Endocrinol Metab. 2009 May;94(5):1689-94. doi: 10.1210/jc.2008-1940. Epub 2009 Mar 10.
Fahrbach J, Jacober S, Jiang H, Martin S. The DURABLE trial study design: comparing the safety, efficacy, and durability of insulin glargine to insulin lispro mix 75/25 added to oral antihyperglycemic agents in patients with type 2 diabetes. J Diabetes Sci Technol. 2008 Sep;2(5):831-8. doi: 10.1177/193229680800200514.
Scheen AJ, Schmitt H, Jiang HH, Ivanyi T. Individualizing treatment of type 2 diabetes by targeting postprandial or fasting hyperglycaemia: Response to a basal vs a premixed insulin regimen by HbA1c quartiles and ethnicity. Diabetes Metab. 2015 Jun;41(3):216-22. doi: 10.1016/j.diabet.2015.03.002. Epub 2015 Apr 14.
Jovanovic L, Peters AL, Jiang HH, Hardin DS. Durability of glycemic control with insulin lispro mix 75/25 versus insulin glargine for older patients with type 2 diabetes. Aging Clin Exp Res. 2014 Apr;26(2):115-21. doi: 10.1007/s40520-013-0140-8. Epub 2013 Oct 3.
Wolffenbuttel BH, Herman WH, Gross JL, Dharmalingam M, Jiang HH, Hardin DS. Ethnic differences in glycemic markers in patients with type 2 diabetes. Diabetes Care. 2013 Oct;36(10):2931-6. doi: 10.2337/dc12-2711. Epub 2013 Jun 11.
Qu Y, Jacober SJ, Zhang Q, Wolka LL, DeVries JH. Rate of hypoglycemia in insulin-treated patients with type 2 diabetes can be predicted from glycemic variability data. Diabetes Technol Ther. 2012 Nov;14(11):1008-12. doi: 10.1089/dia.2012.0099.
Buse JB, Wolffenbuttel BH, Herman WH, Hippler S, Martin SA, Jiang HH, Shenouda SK, Fahrbach JL. The DURAbility of Basal versus Lispro mix 75/25 insulin Efficacy (DURABLE) trial: comparing the durability of lispro mix 75/25 and glargine. Diabetes Care. 2011 Feb;34(2):249-55. doi: 10.2337/dc10-1701.
Miser WF, Arakaki R, Jiang H, Scism-Bacon J, Anderson PW, Fahrbach JL. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial. Clin Ther. 2010 May;32(5):896-908. doi: 10.1016/j.clinthera.2010.05.001.
Wolffenbuttel BH, Klaff LJ, Bhushan R, Fahrbach JL, Jiang H, Martin S. Initiating insulin therapy in elderly patients with Type 2 diabetes: efficacy and safety of lispro mix 25 vs. basal insulin combined with oral glucose-lowering agents. Diabet Med. 2009 Nov;26(11):1147-55. doi: 10.1111/j.1464-5491.2009.02824.x.
Buse JB, Wolffenbuttel BH, Herman WH, Shemonsky NK, Jiang HH, Fahrbach JL, Scism-Bacon JL, Martin SA. DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. Diabetes Care. 2009 Jun;32(6):1007-13. doi: 10.2337/dc08-2117. Epub 2009 Mar 31.
Public notes

Contacts
Principal investigator
Name 0 0
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Address 0 0
Eli Lilly and Company
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT00279201